98 05909-0
IPOS.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 265/36, 413/12, 413/06, 417/12, A61K 31/535 — A1

(11) International Publication Number: WO 97/45419

(43) International Publication Date: 4 December 1997 (04.12.97)

(21) International Application Number: PCT/US97/08524

(22) International Filing Date: 20 May 1997 (20.05.97)

(30) Priority Data:
60/018,383 — 29 May 1996 (29.05.96) — US
60/040,208 — 6 March 1997 (06.03.97) — US

(71) Applicant *(for all designated States except US)*: WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BELLIOTTI, Thomas [US/US]; 6125 Lodi Lane, Saline, MI 48176 (US). WISE, Lawrence, David [US/US]; 1241 Barrister, Ann Arbor, MI 48105 (US). WUSTROW, David, Juergen [US/US]; 5101 John Holmes Road, Ann Arbor, MI 48103 (US).

(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.


(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.


(54) Title: BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS

(57) Abstract

Compounds having formulae (I) or (II) wherein R^1 and R^2 are independently hydrogen or C_1-C_6 alkyl; X is N or CH; and R^3 is phenyl, naphthyl, heteroaryl, substituted phenyl, substituted naphthyl or substituted heteroaryl, wherein each substituent is independently selected from halogen, C_1-C_6 alkoxy, C_1-C_6 alkyl, -CN, $-CF_3$, or sulphonamido, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, are antagonists of dopamine D4 receptors.



(I)



(II)